Clinical Trials Sponsored by Furesø Kommune

Total 2176 results

Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Multiple Myeloma | B-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma

China
Immune Oncology Research Institute
Agenus Inc.

Recruiting

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Lymphoma

Armenia
Georgetown University
Immune System Key Ltd

Recruiting

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Solid Tumor | KRAS Mutation-Related Tumors

United States
Immune Cell, Inc.
Weifang People's Hospital

Recruiting

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

B Cell Lymphoma | B Cell Leukemia

China
Immune Cell, Inc.
Weifang People's Hospital

Recruiting

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma

China
Skane University Hospital
AC Immune SA

Completed

Optimization of Morphomer-based Alpha-synuclein PET Tracers

Parkinson Disease | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Dementia With Lewy Bodies

Sweden
Immune Design
Merck Sharp & Dohme LLC

Terminated

Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

Follicular Low Grade Non-Hodgkin's Lymphoma
Rockefeller University
Immune Design; IDRI Corporation

Completed

The Effects of GLA on Human Volunteers

Healthy Volunteers

United States
Forest Laboratories

Completed

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Hypertension

United States
Forest Laboratories

Completed

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States, Canada
Forest Laboratories

Completed

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder (VLZ-MD-05)

Generalized Anxiety Disorder

United States
Forest Laboratories

Completed

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Diafert for Embryo Selection and Fertility Improvement (DESTINy) (DESTINy)

Infertility

Hungary
Forest Laboratories

Terminated

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Neoplasms | Febrile Neutropenia

United States
Forest Laboratories

Completed

PR-018: An Open-Label, Safety Extension of Study PR-011

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

Chronic Pancreatitis | Exocrine Pancreatic Insufficiency | Pancreatectomy

Canada, United States, Poland, Slovakia
Forest Laboratories

Completed

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

Bacterial Infection

United States
Forest Laboratories

Completed

Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025)

Nausea

Canada
Forest Laboratories

Completed

Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)

Nausea

Canada
Forest Laboratories

Completed

Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Dyspepsia
Forest Laboratories

Completed

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Dyspepsia

Canada
Forest Laboratories

Completed

Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Dyspepsia
Forest Laboratories

Completed

Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient

Congestive Heart Failure

United States
Forest Laboratories

Completed

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

Infections | Pneumonia

United States, Ukraine, Argentina, Georgia
Forest Laboratories

Completed

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

Schizophrenia

United States
Forest Laboratories

Completed

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine, Australia, Canada, France, Singapore
Forest Laboratories

Completed

Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

Germany, Poland
Forest Laboratories

Completed

Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Study of Oglemilast for the Prevention of Asthma.

Exercise-Induced Asthma

United States
Forest Laboratories

Completed

Study of Oglemilast for the Treatment of Asthma

Asthma

United States
Forest Laboratories

Completed

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

Schizophrenia

United States
Forest Laboratories

Completed

Study of Escitalopram in Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

Bipolar Disorder

United States
Forest Laboratories

Completed

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators

Arrhythmia

United States, Canada, Germany, Belgium, France, Italy, Netherlands, Poland, Spain
Forest Laboratories

Completed

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

Hypertension

United States, Puerto Rico
Forest Laboratories

Completed

The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease

Coronary Artery Disease | Hypertension

United States
Forest Laboratories

Completed

A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients

Hypertension

United States
Forest Laboratories

Completed

Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia

Schizophrenia

United States
University of Bergen
Yale University; Leiden University; Harvard University; Bergen kommune; Tohoku University

Recruiting

Decoding Death and Dying in People With Dementia by Digital Thanotyping (5-D)

Dementia

Norway
Anne Estrup Olesen
Frederikshavn Kommune, Frederikshavn, Denmark; Lægeklinikken Frederikshavn,...

Completed

Deprescribing and Health-related Effects

Chronic Disease

Denmark
Ove Andersen
Aalborg University; Albertslund Kommune; Gate 21; Chromaviso A/S

Completed

Circadian Adjusted LED Light's Effect in People Living in Elderly Housing (Lightel)

Elderly Housing Residents With Frailty or Dementia

Denmark
Forest Laboratories

Completed

A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically (LIN-PK-01)

Irritable Bowel Syndrome | Constipation | Breast Feeding

United States
Forest Laboratories

Completed

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Forest Laboratories

Completed

Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Forest Laboratories

Completed

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

Autistic Disorder | Autism | Autism Spectrum Disorders | Asperger Syndrome | Asperger's Disorder | Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, France, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine

Clinical Trials Sponsored by Furesø Kommune

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations